(Q34932593)

5 August 2017

1 reference

title

Amyloid-beta immunotherapy for Alzheimer's disease: the end of the beginning (English)

1 reference

5 August 2017

0 references

1 reference

Dale Schenk

1 reference

5 August 2017

language of work or name

English

0 references

publication date

1 October 2002

1 reference

Nature Reviews Neuroscience

5 August 2017

published in

1 reference

5 August 2017

1 reference

5 August 2017

1 reference

5 August 2017

page(s)

824-828

1 reference

Dosing in phase II trial of Alzheimer's vaccine suspended

5 August 2017

cites work

1 reference

The gene defects responsible for familial Alzheimer's disease

31 March 2020

1 reference

New insights into the genetics of Alzheimer's disease

31 March 2020

1 reference

Mutation of the beta-amyloid precursor protein in familial Alzheimer's disease increases beta-protein production

31 March 2020

1 reference

Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid beta-protein in both transfected cells and transgenic mice

31 March 2020

1 reference

An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants.

31 March 2020

1 reference

Familial Alzheimer's disease-linked presenilin 1 variants elevate Abeta1-42/1-40 ratio in vitro and in vivo

31 March 2020

1 reference

Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease

31 March 2020

1 reference

Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse

31 March 2020

1 reference

A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease

31 March 2020

1 reference

A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease

31 March 2020

1 reference

Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice

31 March 2020

1 reference

Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease

31 March 2020

1 reference

Peripheral anti-A beta antibody alters CNS and plasma A beta clearance and decreases brain A beta burden in a mouse model of Alzheimer's disease

31 March 2020

1 reference

Brain to plasma amyloid-beta efflux: a measure of brain amyloid burden in a mouse model of Alzheimer's disease

31 March 2020

1 reference

Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model

31 March 2020

1 reference

Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer beta-amyloid peptide

31 March 2020

1 reference

Disaggregation of Alzheimer beta-amyloid by site-directed mAb.

31 March 2020

1 reference

Non-Fc-mediated mechanisms are involved in clearance of amyloid-beta in vivo by immunotherapy.

31 March 2020

1 reference

Immunization against Alzheimer's beta -amyloid plaques via EFRH phage administration

31 March 2020

1 reference

31 March 2020

Identifiers

DOI

10.1038/NRN938

1 reference

Dimensions Publication ID

5 August 2017

1039701528

0 references

1 reference